ArticleClinical, cosmetic and investigational dermatology2026
Thiopurine Methyltransferase Levels and Azathioprine Outcomes in Thai Patients with Cutaneous Autoimmune Diseases.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thiopurine methyltransferase (TPMT) is responsible for the inactivation of azathioprine, and is widely used to treat cutaneous autoimmune diseases. TPMT activity is inherited as an autosomal codominant trait and ranges from high to undetectable levels in different individuals. Low TPMT activity may result in a higher risk of adverse effects (AEs), whereas high TPMT activity may result in potential treatment failure. Objective: To assess TPMT levels in patients with cutaneous autoimmune diseases and evaluate the correlation between TPMT levels and AEs of azathioprine and clinical response in patients with pemphigus. Methods: A cross-sectional study was conducted in 300 patients with cutaneous autoimmune diseases. Blood samples were collected to identify TPMT levels by ELISA. In 10 patients with the lowest TPMT levels, subsequent PCR analysis for the Results: Among 300 patients, pemphigus vulgaris was diagnosed in 93 (31%), lupus erythematosus in 93 (31%), pemphigus foliaceus in 39 (13%), bullous pemphigoid in 32 (10.7%), systemic sclerosis in 26 (8.7%), and other diseases in 17 (5.6%). The mean TPMT level was 84.9 ± 30.5 mU/mL. Alcohol consumption significantly correlated with lower TPMT levels (p = 0.005). TPMT levels were not correlated with AEs (p = 0.184). The Conclusion: Alcohol consumption resulted in lower TPMT levels. TPMT levels did not correlate with clinical response in the pemphigus group and AEs. These findings provide real-world clinical insight in Thai patients, where routine TPMT screening is not universally implemented, highlighting the need for alternative predictors of azathioprine toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.